Physician profile
Aaron A Jasper
NPI 1780132290
$4,622.09
in general payments reported to CMS, 2019-2025
27 companies · $2,038 in 2025
The $2,038 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.13 · 2022: $343 · 2023: $236 · 2024: $1,989 · 2025: $2,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,238 · Education: $25.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,237.71 |
| Education | $25.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,170.37 | 2021-2025 | |
| Novo Nordisk INC | $638.87 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $536.94 | 2024-2025 | |
| Lilly USA, LLC | $414.05 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $334.53 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $249.72 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Axsome Therapeutics, INC. | $185.90 | 2025 | Auvelity |
| Esperion Therapeutics, INC. | $160.27 | 2024-2025 | Nexletol |
| Ucb, INC. | $154.66 | 2024 | Briviact, Nayzilam |
| Takeda Pharmaceuticals U.S.A., INC. | $134.57 | 2024-2025 | Trintellix |
| Jazz Pharmaceuticals INC. | $123.10 | 2023 | |
| Exact Sciences Corporation | $99.06 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.89 | 2024-2025 | Caplyta |
| Amgen INC. | $52.95 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.19 | 2025 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $39.79 | 2025 | Xyosted |
| Insulet Corporation | $30.39 | 2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.30 | 2024-2025 | Xifaxan |
| Tris Pharma INC | $23.23 | 2024 | Dyanavel Xr |
| Corium, LLC | $21.43 | 2025 | Azstarys |
| Tandem Diabetes Care, INC. | $21.32 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Impel Pharmaceuticals INC. | $17.33 | 2022 | |
| Atland Pharmaceuticals, LLC | $16.43 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Abbott Laboratories | $14.55 | 2023 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $14.33 | 2024 | |
| Phathom Pharmaceuticals, INC. | $9.93 | 2024 | Voquezna |
| Genentech USA, INC. | $1.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Jasper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.